NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.
NeuroPace, Inc. NPCE is tightening its focus on the core RNS franchise as it exits the DIXI distribution and leans into workflow upgrades designed to expand clinician capacity. The company is positioning software, not just hardware, as the next lever for growth as utilization rises at comprehensive epilepsy centers.
At the same time, clinical momentum and a potential idiopathic generalized epilepsy expansion remain key swing factors, with timing and coverage dynamics still shaping the path from catalyst to revenue.
NeuroPace has rebranded Seizure ID as the ECoG Assistant and is positioning it as the first commercial artificial intelligence workflow tool in its broader suite. The near-term goal is practical: help clinicians review intracranial electroencephalography more efficiently and identify likely electrographic seizures with less manual effort.
Management has framed the payoff around reduced workflow friction at high-utilizing centers. If physicians spend less time on time-intensive review tasks, the same teams can support more patients without adding proportional labor, which matters most where demand is already high.
Alongside ECoG Assistant, NeuroPace is migrating its clinician platform to the cloud to improve scalability and accelerate software deployment. In effect, the company is building an architecture that can push updates faster and support growth without turning every incremental user into an incremental support burden.
That matters for adoption because software improvements are only commercial drivers if they can reach the field smoothly. A cloud foundation is intended to lower barriers for new physician adoption while supporting faster iteration as additional tools and remote care initiatives roll out.
In commercial terms, “throughput” is about how many patients a center can manage and follow over time. NeuroPace’s workflow initiatives are designed to make the RNS System easier to run at scale, which can make the platform stickier as clinicians expand their active patient panels.
If centers can handle more monitoring and programming efficiently, procedure consistency can improve over time. Quarterly timing can still swing results because procedure cadence is inherently variable, but a smoother workflow can help reduce friction that slows scheduling and follow-up at busy sites.
A core differentiator of the RNS System is continuous brain activity data paired with remote review to inform ongoing therapy adjustments. That combination can deepen clinical engagement because clinicians can use longitudinal intracranial electroencephalography information to refine programming over time.
As utilization grows, that ongoing review loop can reinforce long-term platform differentiation. The more the workflow supports consistent review and adjustments, the more the system becomes embedded in routine epilepsy care at treating centers.
Clinical updates have helped sustain momentum. NeuroPace highlighted three-year Post-Approval Study results showing an 82% median seizure reduction among 324 focal epilepsy patients across 32 U.S. centers. The company also shared 12- and 18-month updates from the NAUTILUS idiopathic generalized epilepsy trial, with 18-month results showing a 77% median reduction in generalized tonic-clonic seizures, fewer injury events, and reduced rescue medication use.
The regulatory pathway is progressing, but monetization timing still depends on review and coverage. A premarket approval supplement for idiopathic generalized epilepsy was submitted in mid-December 2025 and remains under review, with management targeting a midyear determination. The company has also been building commercial groundwork through referral training, CARE community access, and programming centers to support adoption if and when clearance and payer coverage broaden.
Image Source: Zacks Investment Research
The near-term timing risks are straightforward. ECoG Assistant is expected to be the first commercial artificial intelligence tool, with a targeted second-quarter 2026 approval window, but regulatory clearance and field adoption can slip. The cloud transition also introduces execution risk if implementation takes longer than planned or slows deployment velocity.
Idiopathic generalized epilepsy carries its own nuance. The FDA paused the review clock to request follow-up information, and management has responded while still viewing a midyear determination as on track. At the same time, the company has disclosed that the primary effectiveness endpoint at one year did not reach statistical significance in the overall NAUTILUS study, which can influence review dynamics and payer conversations.
Scaling beyond Level 4 comprehensive epilepsy centers depends on converting identification into implants with less friction. NeuroPace’s plan includes targeted sales representative additions, incentive structure updates, and added patient-navigation resources designed to help patients move from identification to implant.
This go-to-market work is aimed at making community referral relationships more productive without overwhelming implanting centers. Over time, that could broaden the funnel while keeping procedures concentrated at experienced sites where the workflow is already established.
Valuation is not stretched versus the broader market, but it is clearly elevated versus medical peers. NPCE trades at 5.32 times forward enterprise value-to-sales, slightly above the S&P 500 at 5.21 times but well above the industry at 4.05 times and the sector at 2.45 times.
Image Source: Zacks Investment Research
The 2026 watchlist starts with workflow catalysts: the artificial intelligence approval target window for ECoG Assistant in the second quarter of 2026 and tangible progress on cloud migration that supports faster software deployment.
Next, watch for signs that funnel expansion is translating into sustained conversion, particularly as management expects seasonality to favor the second half and commercial investments to become more productive as 2026 progresses.
Finally, track clarity on idiopathic generalized epilepsy determination and the pace of payer coverage evolution, since management’s 2026 outlook excludes any idiopathic generalized epilepsy contribution and implies coverage and workflow build can lag clearance.
Image Source: Zacks Investment Research
Companies like LivaNova LIVN, currently carrying a Zacks Rank #3 (Hold) and Boston Scientific $BSX BSX, carrying a Zacks Rank #4 (Sell), show how neuromodulation platforms can compound value when upgrades improve usability and expand addressable settings. NeuroPace’s 2026 execution will hinge on turning software efficiency and regulatory milestones into durable center-level adoption.
NPCE presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X $TWTR Imaging which shot up +129.6% in little more than 9 months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
LivaNova PLC (LIVN): Free Stock Analysis Report
NeuroPace, Inc. (NPCE): Free Stock Analysis Report
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
